Back to top
more

Collegium Pharmaceutical (COLL)

(Delayed Data from NSDQ)

$31.09 USD

31.09
321,344

+1.02 (3.39%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $31.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Zacks Equity Research

AMRX vs. COLL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Zacks Equity Research

AMRX or COLL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Zacks Equity Research

AMRX or COLL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMRX vs. COLL: Which Stock Is the Better Value Option?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Top Ranked Growth Stocks to Buy for April 6th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 6th

Zacks Equity Research

Top Ranked Growth Stocks to Buy for April 1st

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 1st

Zacks Equity Research

COLL or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

COLL vs. NBIX: Which Stock Is the Better Value Option?

Zacks Equity Research

Top Ranked Growth Stocks to Buy for March 20th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 20th

Zacks Equity Research

COLL or NBIX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

COLL vs. NBIX: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Collegium (COLL) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).

Zacks Equity Research

Assertio (ASRT) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

Kinjel Shah headshot

Prospects Appear Bright for Small Drug Industry in 2020

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.

Zacks Equity Research

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Collegium Pharmaceutical (COLL) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -12.50% and -1.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Collegium Pharmaceutical (COLL) Q2 Earnings Expected to Decline

by Zacks Equity Research

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Collegium Pharmaceutical (COLL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?